(NASDAQ: OVID) Ovid Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.22%.
Ovid Therapeutics's earnings in 2026 is -$34,492,000.On average, 12 Wall Street analysts forecast OVID's earnings for 2026 to be -$74,135,067, with the lowest OVID earnings forecast at -$78,470,679, and the highest OVID earnings forecast at -$71,771,962. On average, 12 Wall Street analysts forecast OVID's earnings for 2027 to be -$82,747,702, with the lowest OVID earnings forecast at -$101,437,707, and the highest OVID earnings forecast at -$63,569,452.
In 2028, OVID is forecast to generate -$94,953,818 in earnings, with the lowest earnings forecast at -$124,404,735 and the highest earnings forecast at -$63,569,452.